Is it necessary to conduct trials with trimethoprim-sulphamethoxazole amongst HIV-infected individuals in Africa?
Samb
B
B
Badiane
M
M
Kony
S
S
Larouzé
B
B
Faye
M A
MA
Sow
P S
PS
Badiane
S
S
Metro
A
A
Costagliola
D
D
Ndoye
I
I
Delaporte
E
E
Coll-Seck
A M
AM
Coulaud
J P
JP
D017088:AIDS-Related Opportunistic Infections / Q000517:prevention & control*; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D011020:Pneumonia, Pneumocystis / Q000517:prevention & control; D012675:Senegal; D014123:Toxoplasmosis / Q000517:prevention & control; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000009:adverse effects / Q000627:therapeutic use*
D000890:Anti-Infective Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination